Flavonoids and survival in stage III colon cancer: CALGB/SWOG 80702 (Alliance)
JNCI Cancer Spectrum · 02.11.2026 · 10 (6)
DOI: 10.1093/jncics/pkag112 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 21.10.2026. Verfasst von Seohyuk Lee und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United States. Hauptthemen laut MEDLINE: Colonic Neoplasms, Flavonoids, Diet. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
We sought to evaluate the associations of postdiagnostic consumption of flavonoids and flavonoid-rich foods with survival among patients with stage III colon cancer enrolled in a clinical trial.
Methods
We conducted a prospective observational study of 1625 patients with stage III colon cancer enrolled in the CALGB/SWOG 80702 (Alliance) randomized adjuvant chemotherapy trial who completed a self-reported food frequency questionnaire within 6 weeks of and again 14-16 months postrandom assignment. Intakes of flavonoids overall and by subclasses (anthocyanidins, flavanones, flavan-3-ols, flavones, flavonols, isoflavones) were computed by multiplying the consumption frequency of each dietary item by the nutrient content of its respective specified portions. Multivariable analyses for the primary (disease-free survival [DFS]) and secondary (OS) endpoints were adjusted for sociodemographic, clinical, dietary, and lifestyle factors. Bonferroni corrections were applied for analyses of flavonoid subclasses and flavonoid-rich foods.
Results
Over median follow-up of 5.9 years, flavonoid consumption either overall or by subclasses was not statistically significantly associated with survival outcomes, with a hazard ratio of 1.01 (95% CI = 0.75 to 1.37) for DFS among those in the highest relative to lowest consumption quintiles of total flavonoids. Exploratory analyses of flavonoid-rich foods intake did not demonstrate statistically significant associations with DFS or overall survival after Bonferroni correction.
Conclusion
Among resected stage III colon cancer patients who received standardized treatment and follow-up within a nationwide randomized clinical trial, consumption of flavonoids was not associated with survival outcomes. ClinicalTrials.gov identifier NCT01150045.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United States.
- Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States.
- Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA, United States.
- Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, United States.
- Department of Medical Oncology, Illinois CancerCare PC, Peoria, IL, United States.
- Department of Medical Oncology, Hôtel-Dieu de Québec, Québec, QC, Canada.
ORCID-Profile: Seohyuk Lee, Chao Ma, Qian Shi, Pankaj Kumar, Smitha Krishnamurthi, Jeffrey A Meyerhardt
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Lee, S., Ma, C., Shi, Q., Kumar, P., Couture, F., Kuebler, P., Krishnamurthi, S., Tan, B., Shergill, A., O'Reilly, E. M., Shields, A. F., & Meyerhardt, J. A. (2026). Flavonoids and survival in stage III colon cancer: CALGB/SWOG 80702 (Alliance). JNCI Cancer Spectrum, 10(6). https://doi.org/10.1093/jncics/pkag112
Vancouver
Lee S, Ma C, Shi Q, Kumar P, Couture F, Kuebler P, et al. Flavonoids and survival in stage III colon cancer: CALGB/SWOG 80702 (Alliance). JNCI Cancer Spectrum. 2026;10(6). doi:10.1093/jncics/pkag112
BibTeX
@article{Lee2026,
author = {Lee, Seohyuk and Ma, Chao and Shi, Qian and Kumar, Pankaj and Couture, Felix and Kuebler, Philip and Krishnamurthi, Smitha and Tan, Benjamin and Shergill, Ardaman and O'Reilly, Eileen M and Shields, Anthony F and Meyerhardt, Jeffrey A},
title = {Flavonoids and survival in stage III colon cancer: CALGB/SWOG 80702 (Alliance)},
journal = {JNCI Cancer Spectrum},
year = {2026},
volume = {10},
number = {6},
doi = {10.1093/jncics/pkag112}
}
EUVIMED